Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (207)	4/8/2002 4:02:40 PM
From: rkrw	Read Replies (1) \| Respond to of 508

quid, I think they'll test perfenidone in combo with actimmune. My guess is post actimmune approval, they'll try dropping the prednisone and replacing it with pirfenidone to see if there's any synergy. Pirfenidone is an oral drug which is appealing for a combo. This is a nice, logical, low risk and low cost move for itmn imo.

To: quidditch who wrote (207)	4/8/2002 5:44:51 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 508

<Seems as though the Rochester Mayo Clinic hasn't found anything it likes in the anti-fibrotic drugs (a few weeks ago, someone posted a very negative interpretation from some RMC investigators who had reviewed the ITMN study of the effects of actimmune in ipf in a 19-patient trial).> I don't want to be picky but this statement is not correct. The RMC work was a meta-study in which they looked at the records of patients who had been treated at Mayo. I do not think that it was in any way a "review" of an ITMN study. It did cast a shadow on the favorable data that is coming out. ij